Good to see some additional homegrown activity and a useful addition to their future sales pipeline but the UK based GvHD trial should remain their main focus right now.
Ann: Efficacy for CYP MSC Technology in Preclinical Asthma Study-CYP.AX, page-12
Add CYP (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
26.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $46.70M | |||
| Open | High | Low | Value | Volume |
| 26.0¢ | 26.5¢ | 26.0¢ | $22.52K | 86.65K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 34500 | 25.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 26.5¢ | 8292 | 2 |
View Market Depth
| Last trade - 15.25pm 19/07/2024 (20 minute delay) ? |
| CYP (ASX) Chart |